MedTrace Logo

Assay to Measure Beta Blocker Adherence

NCT05251974 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 27

Last updated 2023-11-22

No results posted yet for this study

Summary

This study will assess the feasibility and efficacy of using serum assay developed by Quest Diagnostics to detect the presence of beta blockers, specifically carvedilol and metoprolol succinate, in patients with heart failure.

Conditions

  • Congestive Heart Failure
  • Medication Adherence

Interventions

DIAGNOSTIC_TEST

Quest beta blocker assay

Blood assay to detect presence of beta blocker medications

Sponsors & Collaborators

  • Quest Diagnostics-Nichols Insitute

    collaborator INDUSTRY

  • Summa Health System

    lead OTHER

Principal Investigators

  • Kenneth Varian, MD · Summa Health System

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-02
Primary Completion
2023-11-15
Completion
2023-11-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05251974 on ClinicalTrials.gov